Immunome, Inc. (NASDAQ:IMNM – Get Free Report) CFO Max Rosett sold 14,380 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the sale, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Immunome Trading Down 2.0 %
IMNM traded down $0.30 during trading hours on Friday, hitting $14.99. The company’s stock had a trading volume of 1,948,571 shares, compared to its average volume of 783,200. The company has a 50-day simple moving average of $14.51 and a 200 day simple moving average of $16.24. The firm has a market capitalization of $898.94 million, a PE ratio of -1.99 and a beta of 1.77. Immunome, Inc. has a fifty-two week low of $6.65 and a fifty-two week high of $30.96.
Immunome (NASDAQ:IMNM – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.62 million. Research analysts expect that Immunome, Inc. will post -1.92 earnings per share for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Analysis on Immunome
Hedge Funds Weigh In On Immunome
Several large investors have recently bought and sold shares of IMNM. Avidity Partners Management LP bought a new stake in shares of Immunome in the 4th quarter worth $14,268,000. Mayo Clinic bought a new stake in Immunome in the fourth quarter worth about $1,161,000. Lord Abbett & CO. LLC bought a new stake in Immunome in the first quarter worth about $10,994,000. Swiss National Bank bought a new position in shares of Immunome during the 1st quarter valued at about $1,762,000. Finally, Sofinnova Investments Inc. boosted its position in shares of Immunome by 10.3% during the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock valued at $7,934,000 after purchasing an additional 61,284 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.
Immunome Company Profile
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Recommended Stories
- Five stocks we like better than Immunome
- Where to Find Earnings Call Transcripts
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Stock Splits, Do They Really Impact Investors?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.